Leerink Partnrs Issues Positive Outlook for TRVI Earnings

Trevi Therapeutics, Inc. (NASDAQ:TRVI) – Research analysts at Leerink Partnrs lifted their Q1 2025 earnings estimates for Trevi Therapeutics in a note issued to investors on Tuesday, March 18th. Leerink Partnrs analyst F. Khurshid now expects that the company will post earnings per share of ($0.10) for the quarter, up from their previous estimate of ($0.13). The consensus estimate for Trevi Therapeutics’ current full-year earnings is ($0.49) per share. Leerink Partnrs also issued estimates for Trevi Therapeutics’ Q2 2025 earnings at ($0.11) EPS, Q4 2025 earnings at ($0.12) EPS, FY2025 earnings at ($0.45) EPS and FY2026 earnings at ($0.45) EPS.

Trevi Therapeutics (NASDAQ:TRVI) last posted its earnings results on Tuesday, March 18th. The company reported ($0.11) earnings per share for the quarter, beating the consensus estimate of ($0.12) by $0.01.

A number of other equities analysts have also recently commented on the stock. D. Boral Capital reissued a “buy” rating and issued a $21.00 price objective on shares of Trevi Therapeutics in a research note on Wednesday. Needham & Company LLC dropped their price objective on shares of Trevi Therapeutics from $25.00 to $24.00 and set a “buy” rating for the company in a research note on Wednesday. Raymond James raised shares of Trevi Therapeutics from an “outperform” rating to a “strong-buy” rating and lifted their price objective for the stock from $9.00 to $29.00 in a research note on Monday, March 10th. B. Riley reissued a “buy” rating and issued a $20.00 price objective (up from $11.00) on shares of Trevi Therapeutics in a research note on Wednesday. Finally, HC Wainwright reissued a “buy” rating and issued a $12.50 price objective on shares of Trevi Therapeutics in a research note on Wednesday. Seven equities research analysts have rated the stock with a buy rating and three have issued a strong buy rating to the company. According to MarketBeat.com, the company has an average rating of “Buy” and a consensus target price of $17.56.

Trevi Therapeutics Stock Performance

TRVI opened at $6.61 on Friday. Trevi Therapeutics has a fifty-two week low of $2.30 and a fifty-two week high of $7.39. The stock has a market capitalization of $508.08 million, a price-to-earnings ratio of -15.02 and a beta of 0.90. The company has a fifty day moving average of $4.55 and a 200 day moving average of $3.73.

Institutional Investors Weigh In On Trevi Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in TRVI. Point72 Asset Management L.P. bought a new stake in Trevi Therapeutics during the 4th quarter valued at about $17,099,000. Frazier Life Sciences Management L.P. lifted its holdings in Trevi Therapeutics by 44.5% during the 4th quarter. Frazier Life Sciences Management L.P. now owns 10,664,774 shares of the company’s stock valued at $43,939,000 after buying an additional 3,283,684 shares in the last quarter. Woodline Partners LP lifted its holdings in Trevi Therapeutics by 429.9% during the 4th quarter. Woodline Partners LP now owns 3,212,597 shares of the company’s stock valued at $13,236,000 after buying an additional 2,606,370 shares in the last quarter. Adage Capital Partners GP L.L.C. bought a new stake in Trevi Therapeutics during the 4th quarter valued at about $10,300,000. Finally, Acorn Capital Advisors LLC bought a new stake in Trevi Therapeutics during the 4th quarter valued at about $8,244,000. Institutional investors own 95.76% of the company’s stock.

Insider Buying and Selling

In related news, insider Farrell Simon sold 81,313 shares of Trevi Therapeutics stock in a transaction dated Monday, March 10th. The shares were sold at an average price of $6.75, for a total transaction of $548,862.75. Following the completion of the transaction, the insider now directly owns 76,900 shares of the company’s stock, valued at approximately $519,075. The trade was a 51.39 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 24.37% of the stock is owned by corporate insiders.

About Trevi Therapeutics

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.